News

Healio18h
Long-term weight regain minimal with tirzepatide for adults with obesity, prediabetes
Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...
Where Will Eli Lilly Be in 5 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Eli Lilly Tries to Kill Custom Tirzepatide--But This Healthtech Rebel Isn't Backing Down
OrderlyMeds fights back after Big Pharma crackdown, igniting a battle over the future of personalized medicine ...
The American Journal of Managed Care11h
Discussing Tirzepatide’s Rise in Diabetes, Obesity Care: Jaime Almandoz, MD, MBA
Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake ...
Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence
Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...
Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
Medindia3d
Tirzepatide Supports Long-Term Weight Loss for Three Years
The study, led by Dr. Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that manufacture tirzepatide, is a continuation of the SURMOUNT-1 phase 3 ...